FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Trial Profile

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs FATE NK100 (Primary) ; Cetuximab; Trastuzumab
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Pancreatic cancer; Renal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms DIMENSION
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 20 Feb 2018 According to a Fate Therapeutics media release, Manish R. Patel, D.O., Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota is the principal investigator of the study.
    • 20 Feb 2018 According to a Fate Therapeutics media release, first patient has been treated in this study.
    • 06 Feb 2018 Planned End Date changed from 1 Dec 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top